These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 26001373)

  • 1. New targets to treat obesity and the metabolic syndrome.
    Martin KA; Mani MV; Mani A
    Eur J Pharmacol; 2015 Sep; 763(Pt A):64-74. PubMed ID: 26001373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic syndrome: a critical appraisal based on the CUORE epidemiologic study.
    Giampaoli S; Stamler J; Donfrancesco C; Panico S; Vanuzzo D; Cesana G; Mancia G; Pilotto L; Mattiello A; Chiodini P; Palmieri L;
    Prev Med; 2009 Jun; 48(6):525-31. PubMed ID: 19344739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome.
    Nisoli E; Carruba MO
    Pharmacol Res; 2004 Nov; 50(5):453-69. PubMed ID: 15458765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different obesity phenotypes, and incident cardiovascular disease and mortality events in elderly Iranians: Tehran lipid and glucose study.
    Mirbolouk M; Asgari S; Sheikholeslami F; Mirbolouk F; Azizi F; Hadaegh F
    Geriatr Gerontol Int; 2015 Apr; 15(4):449-56. PubMed ID: 24750352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction.
    Traish AM; Guay A; Feeley R; Saad F
    J Androl; 2009; 30(1):10-22. PubMed ID: 18641413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease.
    Meigs JB; Wilson PW; Fox CS; Vasan RS; Nathan DM; Sullivan LM; D'Agostino RB
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2906-12. PubMed ID: 16735483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of pharmacotherapy in the prevention and treatment of paediatric metabolic syndrome--Implications for long-term health: part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Sabin MA; Magnussen CG; Juonala M; Cowley MA; Shield JP
    Pharmacol Res; 2012 Apr; 65(4):397-401. PubMed ID: 22037094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome.
    Kim B; Feldman EL
    Exp Mol Med; 2015 Mar; 47(3):e149. PubMed ID: 25766618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pharmacotherapy of obesity].
    Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G
    Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease.
    Stern MP; Williams K; Hunt KJ
    Atheroscler Suppl; 2005 May; 6(2):3-6. PubMed ID: 15823490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and metabolic syndrome as related to cardiovascular disease.
    Nikolopoulou A; Kadoglou NP
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):933-9. PubMed ID: 22908926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
    Esser N; Paquot N; Scheen AJ
    Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolic syndrome is associated with subclinical atherosclerosis independent of insulin resistance: the Guangzhou Biobank Cohort Study-CVD.
    Xu L; Jiang CQ; Lam TH; Lin JM; Yue XJ; Cheng KK; Liu B; Jin YL; Zhang WS; Thomas GN;
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):181-8. PubMed ID: 20039893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome.
    Liu J; Grundy SM; Wang W; Smith SC; Vega GL; Wu Z; Zeng Z; Wang W; Zhao D
    Am Heart J; 2007 Apr; 153(4):552-8. PubMed ID: 17383293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.